|

Empagliflozin 10 MG Clinical Trials

11 actively recruiting trials across 3 locations

No change since August 2026

Also known as: Horizon,, Jardiance, Jardiance 10 Mg, Jardiance, Empagliflozin, Jardiance®

Pipeline

Phase 2: 2Phase 3: 2Phase 4: 6Phase 2/3: 1

Top Sponsors

  • Yale University1
  • University Medical Centre Ljubljana1
  • Subodh Verma1
  • Seoul National University Bundang Hospital1
  • Massachusetts General Hospital1

Indications

Other8 trials

A Pragmatic Trial Comparing Empagliflozin and Dapagliflozin Through Cluster Randomization Embedded in the Electronic Health Record
Phase 4
Effect at 3 Months of Early Empagliflozin Initiation in Cardiogenic Shock Patients on Mortality, Rehospitalization, Left Ventricular Ejection Fraction and Renal Function.
Phase 3
Effect of Early Combination Antihyperglycemic Treatment on Metabolic Control in Individuals With Type 2 Diabetes
Phase 4
Effect of Empagliflozin on Quality of Life in Chronic Heart Failure Patients With Diabetes Mellitus Type II
Phase 4
Effects of SGLT2 Inhibitors in Pre-heart Failure Populations With Hypertension
Phase 4
SGLT2 Inhibition With Empagliflozin in Fontan Circulatory Failure
Phase 3
The EMPA-FIT Study
Phase 4
The Treatment Effects of Empagliflozin on Renal Outcomes in Cardiorenal Syndrome Type 1
Phase 2/3

New Haven, Connecticut1 trial

Empagliflozin in Patients With Cirrhosis and Ascites

Yale University

Phase 2

Chicago, Illinois1 trial

Mechanisms of SGLT2 Inhibition in Pediatric Steatotic Liver Disease

Ann & Robert H Lurie Children's Hospital of Chicago

Phase 2

Boston, Massachusetts1 trial

SAVE-Care (Sodium Glucose Cotransporter-2 Inhibitors [SGLT2i] As Novel Gout Care) Trial

Massachusetts General Hospital

Phase 4

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.